Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. (Passion I)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2016 by Novartis
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: December 17, 2010
Last updated: December 30, 2016
Last verified: December 2016
This study will assess pasireotide LAR efficacy on patients with non-functioning pituitary adenomas concerning tumor growth.

Condition Intervention Phase
Non-functioning Pituitary Adenoma
Drug: Pasireotide LAR
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Proportion of patients with non-functioning pituitary adenomas (NFPA) who achieve tumor volume reduction of at least 20% after 24-week treatment with pasireotide LAR [ Time Frame: 24 weeks ]
  • Mean change of tumour volume assessed by pituitary MRI [ Time Frame: from baseline to week 4, 12 and 24 ]

Secondary Outcome Measures:
  • change in tumor volume [ Time Frame: 4, 12 and 24 weeks ]
  • the effect of pasireotide LAR in hormonal response, and relevant disease-related symptoms [ Time Frame: at screening (it will be considered as baseline) and at Weeks 4, 12 and 24. ]
  • Percent change of tumour volume assessed by pituitary MRI [ Time Frame: from baseline to week 4, 12 and 24 ]
  • Proportion of patients achieving tumour volume reduction of at least ≥ 20% [ Time Frame: after 4, 12 and 24 weeks ]

Estimated Enrollment: 23
Study Start Date: November 2012
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pasireotide LAR Drug: Pasireotide LAR


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Non-functioning pituitary adenoma ≥ 1cm, patients without any previous treatment for the tumor
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria:

  • Patients who require a surgical intervention for relief of any sign or symptom associated with tumor compression
  • Previous pituitary surgery
  • Previous medical treatment for pituitary tumor
  • Patients who have received pituitary irradiation within 10 years prior to randomization
  • Prolactin (PRL) levels > 100 ng/mL. PRL evaluation should be performed with diluted samples to make sure to avoid the "hook effect."
  • Patients presenting prolactinomas, acromegaly or Cushing's disease
  • Patients with compression of the optic chiasm causing acute clinically significant visual field defects

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01283542

Contact: Novartis Pharmaceuticals +41613241111
Contact: Novartis Pharmaceuticals

Novartis Investigative Site Recruiting
Fortaleza, CE, Brazil, 04636-000
Novartis Investigative Site Withdrawn
Fortaleza, CE, Brazil, 60020-181
Novartis Investigative Site Recruiting
Sao Luis, MA, Brazil, 65020-070
Novartis Investigative Site Recruiting
Curitiba, PR, Brazil, 80030-110
Novartis Investigative Site Active, not recruiting
Rio de Janeiro, RJ, Brazil, 21941-913
Novartis Investigative Site Recruiting
Joinville, SC, Brazil, 89201260
Novartis Investigative Site Recruiting
Botucatu, SP, Brazil, 18618-970
Novartis Investigative Site Recruiting
Campinas, SP, Brazil
Novartis Investigative Site Recruiting
Sao Paulo, SP, Brazil, 05403-000
Novartis Investigative Site Recruiting
São Paulo, SP, Brazil, 04023-900
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals Identifier: NCT01283542     History of Changes
Other Study ID Numbers: CSOM230D2401
Study First Received: December 17, 2010
Last Updated: December 30, 2016

Keywords provided by Novartis:
Non-functioning pituitary adenoma,
pasireotide LAR,
tumor volume

Additional relevant MeSH terms:
Pituitary Neoplasms
Pituitary Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Hypothalamic Neoplasms
Supratentorial Neoplasms
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms processed this record on May 24, 2017